Nature Communications (Dec 2023)

PAX3-FOXO1 uses its activation domain to recruit CBP/P300 and shape RNA Pol2 cluster distribution

  • Yaw Asante,
  • Katharina Benischke,
  • Issra Osman,
  • Quy A. Ngo,
  • Jakob Wurth,
  • Dominik Laubscher,
  • Hyunmin Kim,
  • Bhavatharini Udhayakumar,
  • Md Imdadul H. Khan,
  • Diana H. Chin,
  • Jadon Porch,
  • Maharshi Chakraborty,
  • Richard Sallari,
  • Olivier Delattre,
  • Sakina Zaidi,
  • Sarah Morice,
  • Didier Surdez,
  • Sara G. Danielli,
  • Beat W. Schäfer,
  • Berkley E. Gryder,
  • Marco Wachtel

DOI
https://doi.org/10.1038/s41467-023-43780-4
Journal volume & issue
Vol. 14, no. 1
pp. 1 – 19

Abstract

Read online

Abstract Activation of oncogenic gene expression from long-range enhancers is initiated by the assembly of DNA-binding transcription factors (TF), leading to recruitment of co-activators such as CBP/p300 to modify the local genomic context and facilitate RNA-Polymerase 2 (Pol2) binding. Yet, most TF-to-coactivator recruitment relationships remain unmapped. Here, studying the oncogenic fusion TF PAX3-FOXO1 (P3F) from alveolar rhabdomyosarcoma (aRMS), we show that a single cysteine in the activation domain (AD) of P3F is important for a small alpha helical coil that recruits CBP/p300 to chromatin. P3F driven transcription requires both this single cysteine and CBP/p300. Mutants of the cysteine reduce aRMS cell proliferation and induce cellular differentiation. Furthermore, we discover a profound dependence on CBP/p300 for clustering of Pol2 loops that connect P3F to its target genes. In the absence of CBP/p300, Pol2 long range enhancer loops collapse, Pol2 accumulates in CpG islands and fails to exit the gene body. These results reveal a potential novel axis for therapeutic interference with P3F in aRMS and clarify the molecular relationship of P3F and CBP/p300 in sustaining active Pol2 clusters essential for oncogenic transcription.